Amit‐ Bar‐or
#128,188
Most Influential Person Now
Amit‐ Bar‐or's AcademicInfluence.com Rankings
Amit‐ Bar‐orphilosophy Degrees
Philosophy
#6106
World Rank
#9080
Historical Rank
Logic
#3296
World Rank
#4429
Historical Rank
Amit‐ Bar‐orbiology Degrees
Biology
#8262
World Rank
#11311
Historical Rank
Neuroscience
#1129
World Rank
#1171
Historical Rank
Download Badge
Philosophy Biology
Amit‐ Bar‐or's Degrees
- PhD Neuroscience Stanford University
- Doctorate Medicine Stanford University
Why Is Amit‐ Bar‐or Influential?
(Suggest an Edit or Addition)Amit‐ Bar‐or's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. (2012) (1465)
- B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (2008) (1332)
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (2017) (1170)
- Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis (2017) (1107)
- IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases (2014) (831)
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial (2011) (625)
- Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis (2007) (584)
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (2018) (559)
- B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells (2012) (540)
- Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial (2008) (476)
- Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS? (2010) (438)
- Comparison of polarization properties of human adult microglia and blood‐derived macrophages (2012) (424)
- A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses (2006) (372)
- Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions (2007) (359)
- Distinct Profiles of Human B Cell Effector Cytokines: A Role in Immune Regulation?1 (2004) (355)
- Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. (2003) (334)
- A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis (2010) (323)
- FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis (2008) (321)
- Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein (2007) (321)
- Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy (2015) (315)
- Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. (2016) (311)
- Serologic diagnosis of NMO (2012) (310)
- Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. (2003) (310)
- Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study (2007) (299)
- Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy (2021) (297)
- Roles of microglia in brain development, tissue maintenance and repair. (2015) (295)
- Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study (2011) (288)
- Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis (2011) (286)
- Incidence of acquired demyelination of the CNS in Canadian children (2009) (283)
- Multiple sclerosis. (2018) (272)
- Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. (2006) (263)
- Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders (2008) (257)
- Teriflunomide and Its Mechanism of Action in Multiple Sclerosis (2014) (256)
- Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial (2016) (247)
- Reassessing B cell contributions in multiple sclerosis (2018) (243)
- NeuriteTracer: A novel ImageJ plugin for automated quantification of neurite outgrowth (2008) (224)
- Ofatumumab versus Teriflunomide in Multiple Sclerosis. (2020) (220)
- The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group (2010) (218)
- Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment1 (2008) (215)
- Natalizumab effects on immune cell responses in multiple sclerosis (2006) (210)
- Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10 (2019) (208)
- Microglia and multiple sclerosis (2005) (199)
- Determinants of Human B Cell Migration Across Brain Endothelial Cells1 (2003) (192)
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis (2018) (188)
- Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis1 (2004) (186)
- miR‐155 as a multiple sclerosis–relevant regulator of myeloid cell polarization (2013) (183)
- The Neuroimmunology of Multiple Sclerosis: Possible Roles of T and B Lymphocytes in Immunopathogenesis (2001) (175)
- Biology of Adult Human Microglia in Culture: Comparisons with Peripheral Blood Monocytes and Astrocytes (1992) (172)
- Multiple sclerosis (2018) (170)
- MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study (2011) (162)
- Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. (2007) (158)
- Neuroinflammation: Ways in Which the Immune System Affects the Brain (2015) (156)
- TLR2 Stimulation Drives Human Naive and Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced Suppressive Function (2011) (155)
- Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. (2005) (155)
- Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS (2005) (153)
- Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation. (2015) (143)
- Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis1 (2009) (140)
- Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years (2012) (138)
- Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes (2019) (137)
- Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro (2012) (136)
- Immunological Memory: Contribution of Memory B Cells Expressing Costimulatory Molecules in the Resting State1 (2001) (136)
- Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies (2019) (136)
- 2010 McDonald criteria for diagnosing pediatric multiple sclerosis (2012) (130)
- Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation (2013) (130)
- P2Y12 expression and function in alternatively activated human microglia (2015) (130)
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study (2016) (130)
- Cell-based therapeutic strategies for multiple sclerosis (2017) (128)
- Neuromyelitis optica with hypothalamic involvement (2005) (128)
- Molecular pathogenesis of multiple sclerosis (1999) (127)
- Trial of Fingolimod versus Interferon Beta‐1a in Pediatric Multiple Sclerosis (2018) (127)
- Treatment of multiple sclerosis with anti-CD20 antibodies. (2012) (126)
- Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis (2011) (125)
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial (2016) (125)
- Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research (2014) (124)
- Obstructive sleep apnea is associated with fatigue in multiple sclerosis (2012) (124)
- A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS (2011) (121)
- Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors (2007) (120)
- B lymphocytes in neuromyelitis optica (2015) (118)
- Distinction and Temporal Stability of Conformational Epitopes on Myelin Oligodendrocyte Glycoprotein Recognized by Patients with Different Inflammatory Central Nervous System Diseases (2013) (116)
- B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation (2015) (115)
- Chronic cerebrospinal venous insufficiency and multiple sclerosis (2010) (115)
- GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study (2009) (113)
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial (2019) (113)
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial (2019) (112)
- Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis (2013) (108)
- Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis (2017) (108)
- Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis (2018) (106)
- Additive effect of the combination of glatiramer acetate and minocycline in a model of MS (2005) (106)
- Update on biomarkers in neuromyelitis optica (2015) (104)
- B cells in multiple sclerosis: connecting the dots. (2011) (103)
- MerTK Is a Functional Regulator of Myelin Phagocytosis by Human Myeloid Cells (2016) (103)
- Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. (2006) (101)
- Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions (2003) (100)
- Coexpression of TIGIT and FCRL3 Identifies Helios+ Human Memory Regulatory T Cells (2015) (100)
- Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. (2014) (99)
- Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. (2009) (94)
- T follicular helper cells in human efferent lymph retain lymphoid characteristics. (2019) (93)
- Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis (2008) (93)
- Roles of immunoglobulins and B cells in multiple sclerosis: From pathogenesis to treatment (2006) (92)
- Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis (2016) (89)
- What do we know about the mechanism of action of disease-modifying treatments in MS? (2004) (88)
- Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia (2007) (88)
- Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation (2015) (87)
- Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
- Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population (2000) (86)
- Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. (2011) (85)
- The immunology of multiple sclerosis. (2008) (85)
- Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis (2018) (84)
- MicroRNA dysregulation in multiple sclerosis (2013) (84)
- Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience (2015) (83)
- Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. (2004) (83)
- Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects (2019) (81)
- A Novel MicroRNA-132-Surtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with Relapsing-Remitting Multiple Sclerosis (2014) (80)
- Lesion distribution in children with clinically isolated syndromes (2008) (80)
- Impact of sleep disorder treatment on fatigue in multiple sclerosis (2013) (79)
- B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro (2017) (78)
- Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis (2010) (76)
- Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis (2017) (75)
- COVID-19 and MS disease-modifying therapies (2020) (74)
- Abnormal T‐cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes (2008) (74)
- Role of B Cells in Multiple Sclerosis and Related Disorders (2020) (73)
- Direct and Indirect Effects of Immune and Central Nervous System–Resident Cells on Human Oligodendrocyte Progenitor Cell Differentiation (2015) (73)
- Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity (2016) (73)
- B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies (2021) (72)
- Differential responses of human microglia and blood-derived myeloid cells to FTY720 (2011) (69)
- Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels (2011) (69)
- Advances in oral immunomodulating therapies in relapsing multiple sclerosis (2020) (66)
- Immune reconstitution therapies: concepts for durable remission in multiple sclerosis (2019) (66)
- MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. (2018) (66)
- Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism (2016) (65)
- Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study (2014) (65)
- International Pediatric MS Study Group Clinical Trials Summit (2013) (65)
- Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis (2015) (62)
- Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances (2021) (62)
- TLR2 Stimulation Regulates the Balance between Regulatory T Cell and Th17 Function: A Novel Mechanism of Reduced Regulatory T Cell Function in Multiple Sclerosis (2015) (62)
- Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study (2015) (62)
- HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination (2011) (60)
- Effect of dimethyl fumarate on lymphocytes in RRMS (2019) (59)
- Five years of ocrelizumab in relapsing multiple sclerosis (2020) (59)
- Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study (2014) (59)
- Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis (2014) (58)
- Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis (2014) (57)
- Reduction of the Peripheral Blood CD56bright NK Lymphocyte Subset in FTY720-Treated Multiple Sclerosis Patients (2011) (57)
- Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study (2013) (57)
- B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators (2008) (56)
- Epitope spreading as an early pathogenic event in pediatric multiple sclerosis (2014) (56)
- Patient and community preferences for treatments and health states in multiple sclerosis (2003) (55)
- Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens (2015) (54)
- Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation (2013) (53)
- Therapies for multiple sclerosis: considerations in the pediatric patient (2011) (53)
- Cytokine‐producing B cells: a translational view on their roles in human and mouse autoimmune diseases (2016) (53)
- Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS (2018) (53)
- Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis (2010) (53)
- Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing‐remitting multiple sclerosis: thymic versus peripheral (non‐thymic) mechanisms (2006) (53)
- Lipid‐specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab (2015) (52)
- Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature (2020) (52)
- Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial (2016) (52)
- Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. (2002) (52)
- Quantitative analysis of human endogenous retrovirus-W env in neuroinflammatory diseases. (2006) (50)
- Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. (2010) (49)
- Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing– remitting multiple sclerosis (2013) (49)
- Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis (2012) (48)
- Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials (2014) (48)
- Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis (2019) (47)
- Regulation of miRNA 219 and miRNA Clusters 338 and 17-92 in Oligodendrocytes (2012) (46)
- Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination (2013) (46)
- Pharmacological Treatment of Early Multiple Sclerosis (2008) (46)
- Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis (2011) (44)
- Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice (2015) (44)
- Elevated serum inflammatory markers in post-poliomyelitis syndrome (2008) (44)
- Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study (2019) (44)
- Dendritic Cell Differentiation Signals Induce Anti-Inflammatory Properties in Human Adult Microglia1 (2008) (43)
- Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination (2016) (42)
- The Relationship between Risk Attitude and Treatment Choice in Patients with Relapsing-Remitting Multiple Sclerosis (2002) (42)
- The Identity of Human Tissue-Emigrant CD8+ T Cells (2020) (42)
- No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a (2018) (41)
- Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10 (2019) (41)
- Siponimod and Cognition in Secondary Progressive Multiple Sclerosis (2020) (41)
- Altered CD 4 / CD 8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis (2006) (41)
- Reduced thymic output and peripheral naïve CD4 T-cell alterations in primary progressive multiple sclerosis (PPMS) (2011) (41)
- Association of HLA-dependent islet autoimmunity with systemic antibody responses to intestinal commensal bacteria in children (2019) (40)
- A proteome map of axoglial specializations isolated and purified from human central nervous system (2010) (40)
- Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis (2018) (40)
- Epstein-Barr virus in oral shedding of children with multiple sclerosis (2013) (40)
- Recovery From Central Nervous System Acute Demyelination in Children (2015) (40)
- High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS (2019) (40)
- Effects of Blood Transportation on Human Peripheral Mononuclear Cell Yield, Phenotype and Function: Implications for Immune Cell Biobanking (2014) (39)
- MerTK-mediated regulation of myelin phagocytosis by macrophages generated from patients with MS (2017) (39)
- Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE (2020) (39)
- White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders (2017) (39)
- Experimental models of neuroprotection relevant to multiple sclerosis (2007) (38)
- Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study (2014) (38)
- Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases (2016) (38)
- Teriflunomide (Aubagio®) for the treatment of multiple sclerosis (2014) (38)
- Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia (2003) (38)
- Fatigue in Post‐poliomyelitis Syndrome: Association With Disease‐Related, Behavioral, and Psychosocial Factors (2009) (37)
- Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial (2021) (37)
- Do myelin-directed antibodies predict multiple sclerosis? (2003) (36)
- Monophasic demyelination reduces brain growth in children (2017) (35)
- Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis (2018) (35)
- A surface‐in gradient of thalamic damage evolves in pediatric multiple sclerosis (2019) (35)
- Polysomnographic measures of disturbed sleep are associated with reduced quality of life in multiple sclerosis (2012) (35)
- Myelin regulates immune cell adhesion and motility (2009) (35)
- CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls. (2003) (34)
- MicroRNA Expression Patterns in Human Astrocytes in Relation to Anatomical Location and Age (2016) (34)
- Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers (2019) (33)
- Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis. (2010) (32)
- Neuroimmune disorders of the central nervous system in children in the molecular era (2018) (32)
- Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study (2018) (32)
- Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials (2013) (31)
- P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions (2020) (30)
- The MIRROR Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and MRI Efficacy of Subcutaneous Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) (S23.006) (2014) (30)
- B-cells in multiple sclerosis. (2006) (30)
- Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod (2017) (29)
- Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses (2017) (29)
- Randomized controlled trial of atorvastatin in clinically isolated syndrome (2012) (29)
- Cyberinfrastructure for Open Science at the Montreal Neurological Institute (2017) (29)
- Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis (2019) (29)
- MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis. (2019) (28)
- Upregulation of TRAIL expression on human T lymphocytes by interferon b and glatiramer acetate (2005) (28)
- Restoring immune tolerance in neuromyelitis optica (2016) (27)
- Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis (2013) (27)
- Glatiramer acetate-reactive T lymphocytes regulate oligodendrocyte progenitor cell number in vitro: Role of IGF-2 (2010) (27)
- Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS (2008) (27)
- Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. (2011) (26)
- Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis (2017) (25)
- Innate Immune-Mediated Neuronal Injury Consequent to Loss of Astrocytes (2008) (25)
- The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk (2019) (24)
- Emerging multiple sclerosis disease-modifying therapies (2009) (23)
- MicroRNA-223 protects neurons from degeneration in Experimental Autoimmune Encephalomyelitis (2018) (23)
- Author Correction: Multiple sclerosis (2018) (23)
- Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS (2014) (23)
- Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis (2020) (22)
- Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies (2016) (22)
- Neuronal microRNA regulation in Experimental Autoimmune Encephalomyelitis (2018) (22)
- Restoring immune tolerance in neuromyelitis optica (2016) (21)
- Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course (2022) (21)
- Immunology of multiple sclerosis. (2005) (21)
- Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study (2018) (21)
- Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system. (2006) (21)
- Masquerades of Acquired Demyelination in Children (2013) (21)
- Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. (2004) (21)
- Multiple sclerosis and related disorders: evolving pathophysiologic insights (2016) (20)
- A condensed performance-validation strategy for multiplex detection kits used in studies of human clinical samples. (2013) (20)
- Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis (2020) (20)
- Laquinimod in multiple sclerosis. (2012) (19)
- Neurite outgrowth is differentially impacted by distinct immune cell subsets (2012) (19)
- Targeting Progressive Neuroaxonal Injury (2011) (19)
- Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial (2013) (18)
- Silent New Brain MRI Lesions in Children with MOG‐Antibody Associated Disease (2020) (18)
- Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study (S49.001) (2016) (18)
- TLR‐mediated B cell activation results in ectopic CLIP expression that promotes B cell‐dependent inflammation (2010) (18)
- Differential transcriptional response profiles in human myeloid cell populations. (2016) (18)
- BTK inhibition limits B-cell–T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy (2022) (17)
- Vaccination and multiple sclerosis in the era of the COVID-19 pandemic (2021) (17)
- High false-positive rate of questionnaire-based restless legs syndrome diagnosis in multiple sclerosis. (2015) (17)
- GLANCE (2009) (17)
- Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results (2021) (17)
- Pediatric-onset multiple sclerosis is associated with reduced parental health–related quality of life and family functioning (2018) (16)
- Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis (2021) (16)
- EBV and brain matter(s)? (2010) (16)
- Exosome-enriched fractions from MS B cells induce oligodendrocyte death (2019) (15)
- Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS (2020) (15)
- Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004) (2016) (15)
- A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis (2010) (15)
- High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc (2015) (14)
- Effect of Ceralifimod (ONO-4641), a Sphingosine-1-Phosphate Receptor-1 and -5 Agonist, on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis: Interim Results from the Extension of the DreaMS Study (P3.161) (2014) (14)
- Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS) (S31.004) (2013) (14)
- Isotype-Switched Autoantibodies Are Necessary To Facilitate Central Nervous System Autoimmune Disease in Aicda−/− and Ung−/− Mice (2018) (14)
- P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN β -1a–controlled OPERA I and OPERA II studies (2017) (14)
- Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study (2021) (14)
- A novel population of B7‐1+ T cells producing intracellular IL‐4 is decreased in patients with multiple sclerosis (2000) (14)
- Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis (2020) (14)
- Mitochondrial DNA haplogroups and mutations in children with acquired central demyelination (2011) (13)
- Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment (2017) (13)
- Rasmussen encephalitis and comorbid autoimmune diseases: A window into disease mechanism? (2014) (13)
- The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies. (2019) (13)
- Incidence and prevalence of MS in children (2018) (13)
- Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis (2020) (13)
- BG-12 (Dimethyl Fumarate) and Pregnancy: Preclinical and Clinical Data from the Clinical Development Program (P02.129) (2013) (13)
- Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations (2020) (13)
- Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases (2021) (12)
- Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. (2021) (12)
- Deep learning segmentation of orbital fat to calibrate conventional MRI for longitudinal studies (2019) (12)
- Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM (2016) (12)
- The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes (2021) (12)
- A tyrosine sulfation–dependent HLA-I modification identifies memory B cells and plasma cells (2018) (12)
- BG-12 Increases the Proportion of Patients Free of Clinical and Radiologic Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (PD5.005) (2012) (12)
- From bench to MS bedside: Challenges translating biomarker discovery to clinical practice (2012) (11)
- High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study (2019) (11)
- Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes (2021) (11)
- Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? (2009) (11)
- Rasmussen encephalitis and comorbid autoimmune diseases (2014) (10)
- Beta interferons in clinically isolated syndromes: a meta-analysis. (2008) (10)
- Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial (2016) (10)
- Myeloid lineage cells inhibit neurite outgrowth through a myosin II-dependent mechanism (2011) (10)
- Central nervous system inflammation across the age span. (2016) (9)
- Human immune studies in multiple sclerosis. (2006) (9)
- Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years (2022) (9)
- Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study (CT.002) (2017) (9)
- Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI (2018) (9)
- A Further TWEAK to Multiple Sclerosis Pathophysiology (2014) (9)
- Unraveling B lymphocytes in CNS inflammatory diseases (2020) (9)
- A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis (S12.006) (2019) (9)
- Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II (2022) (8)
- Emerging therapies to target CNS pathophysiology in multiple sclerosis (2022) (8)
- Efficacy of Ocrelizumab in Patients with Relapsing Multiple Sclerosis: Pooled Analysis of Two Identical Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled Studies (S49.003) (2016) (8)
- Ozanimod Demonstrates Efficacy and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM) (P3.396) (2018) (8)
- Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much? (2009) (8)
- Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis (2020) (8)
- Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial (2022) (8)
- Restoring immune tolerance in neuromyelitis optica: Part I (2018) (8)
- Efficacy Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Adults with Relapsing Multiple Sclerosis (P7.198) (2015) (7)
- Follow-Up Data From the MIRROR Study: A Dose-Ranging Study of Subcutaneous Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (2014) (7)
- Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study (S44.004) (2018) (7)
- Accumulation of meningeal lymphocytes correlates with white matter lesion activity in progressive multiple sclerosis (2022) (7)
- An Exploratory Analysis of Magnetic Resonance Imaging Outcomes in the DreaMS Trial: A Double-Blind, Placebo-Controlled, Phase 2, 26-Week Trial of a Selective Sphingosine 1-Phosphate Receptor Agonist ONO-4641 in Patients with Relapsing–Remitting Multiple Sclerosis (S31.005) (2013) (7)
- Five-Year Follow-up of Delayed-Release Dimethyl Fumarate in RRMS: Integrated Clinical Efficacy Data from the DEFINE, CONFIRM, and ENDORSE Studies (P7.234) (2015) (7)
- B Cells, T Cells and Inflammatory CSF Biomarkers in Primary Progressive MS and Relapsing MS in the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Trial (1635) (2020) (7)
- Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (2018) (7)
- Increased mental health care use by mothers of children with multiple sclerosis (2020) (6)
- BG-12 (dimethyl fumarate) and pregnancy: Preclinical studies and pregnancy outcomes reported during the clinical development program (2013) (6)
- Guilty by association: Epstein–Barr virus in multiple sclerosis (2022) (6)
- Multiple Sclerosis Therapeutics: The immunology of multiple sclerosis (2011) (6)
- Ofatumumab versus teriflunomide in relapsing MS: adaptive design of two Phase 3 studies (ASCLEPIOS I and ASCLEPIOS II) (S16.005) (2017) (6)
- TERI-DYNAMIC: Exploring the Impact of Teriflunomide on Immune Cell Population Size, Receptor Repertoire, and Function in Patients With RRMS (P5.282) (2016) (6)
- Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone (2013) (6)
- Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS (2020) (6)
- Evaluation of no evidence of progression using composite outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial (2016) (6)
- Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies (2021) (6)
- Effects of oral BG-12 (Dimethyl Fumarate) on Magnetic Resonance Imaging (Mri) Outcomes in Relapsing-Remitting Multiple Sclerosis (Rrms): an Integrated Analysis of the Phase 3 Define and Confirm Studies (2012) (6)
- Interim Analysis of the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Study in Multiple Sclerosis (MS) (S24.002) (2018) (6)
- Antigen-specific immunomodulation in multiple sclerosis patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin (2006) (6)
- Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease (2021) (6)
- Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis (P3.084) (2016) (5)
- Antigen-specific therapies in multiple sclerosis (2009) (5)
- Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age (2022) (5)
- Inflammatory mechanisms underlying cortical injury in progressive multiple sclerosis (2020) (5)
- , remitting multiple sclerosis − relapsing Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from (2013) (5)
- Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study (S8.005) (2018) (5)
- Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017) (2015) (5)
- Meningeal B Cell Clusters Correlate with Submeningeal Pathology in a Natural Model of Multiple Sclerosis (2021) (5)
- Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis. (2019) (5)
- Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic (2022) (5)
- Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis (P7.201) (2015) (5)
- Effect of BG-12 on Brain Atrophy and Lesions Volume: MRI Results from the DEFINE Study during First and Second Year of Treatment (IN3-2.002) (2012) (5)
- Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study (2020) (5)
- Improvement of Refractory Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease with Single-Agent Blockade of IL-1β and IL-18 (2022) (5)
- Long-Term Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Week 96 Results of a Phase II, Randomized, Multicenter Trial (S30.006) (2012) (5)
- Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations (2022) (4)
- CLINICAL AND NEURORADIOLOGICAL EFFECT OF BG-12 (DIMETHYL FUMARATE) IN SUBGROUPS OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF THE PHASE 3 DEFINE AND CONFIRM STUDIES (2013) (4)
- Implicating MicroRNAs as Regulators of Microglia and Astrocyte Responses in Human CNS Inflammatory Disease (P5.018) (2014) (4)
- Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria (2022) (4)
- Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.006) (2018) (4)
- Clinical Efficacy of BG-12 (Dimethyl Fumarate) for Relapsing–Remitting Multiple Sclerosis (RRMS) According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P07.128) (2013) (4)
- Effect of the Sphingosine 1-Phosphate Receptor Agonist ONO-4641 on Circulating Lymphocytes in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Phase 2 DreaMS Trial (P05.153) (2013) (4)
- Cross-reactivity between epidemiology and immunology in multiple sclerosis (2008) (4)
- Multiple Sclerosis: Therapy (2004) (4)
- Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid (2016) (4)
- Effects of BG-12 on Magnetization Transfer Ratio in Whole Brain and Normal-Appearing Brain Tissue: Findings from the DEFINE Study (S11.004) (2012) (4)
- Abnormal B-Cell and Tfh-Cell Pro fi les in Patients With Parkinson Disease A Cross-sectional Study (4)
- Factors associated with health care utilization in pediatric multiple sclerosis. (2019) (4)
- “Ependymal‐in” Gradient of Thalamic Damage in Progressive Multiple Sclerosis (2022) (4)
- Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130) (2020) (3)
- MT-1303, a novel selective s1p1 receptor modulator in RRMS - results of a placebo controlled, double blind phase II trial (momentum) (2015) (3)
- Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (S6.002) (2018) (3)
- Multiplexed detection and isolation of viable low-frequency cytokine-secreting human B cells using cytokine secretion assay and flow cytometry (CSA-Flow) (2020) (3)
- Demyelinating Disorders of the Central Nervous System in Childhood: Pediatric MS: biological presentation and research update (2011) (3)
- Effect of Ocrelizumab on Disability Progression in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.008) (2016) (3)
- 12-Year Clinical Efficacy and Safety Data for Teriflunomide: Results from a Phase 2 Extension Study (P7.223) (2015) (3)
- Effects of BG-12 on magnetic resonance imaging outcomes in relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies (2012) (3)
- Author Correction: Immune reconstitution therapies: concepts for durable remission in multiple sclerosis (2020) (3)
- Effects of Long-Term Fingolimod Therapy on Circulating Mononuclear Cell Populations in Multiple Sclerosis (2007) (3)
- Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis (2021) (3)
- Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study (2022) (3)
- Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome (2021) (3)
- The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. (2022) (3)
- Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes (2018) (3)
- Epidural blood patch in a patient with multiple sclerosis: is it safe? (2013) (3)
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase 1 trial (Annals of Neurology (2007) (399-495)) (2008) (3)
- T CELL PROLIFERATION AGAINST MYELIN, PANCREATIC, AND DIETARY ANTIGENS IN CHILDREN: AUTOIMMUNITY IS DETECTABLE EARLY IN CNS DEMYELINATION AND TYPE I DIABETES (2006) (3)
- Safety and Tolerability Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Relapsing Multiple Sclerosis (P7.199) (2015) (3)
- Pathways to cures for multiple sclerosis: A research roadmap (2022) (3)
- Identification of P2Y12 as a mediator of migration and inflammation in human microglia (2014) (3)
- Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.002) (2016) (3)
- A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit (2018) (3)
- Clinical and Magnetic Resonance Imaging Results From RADIANCE Part B, a Multicenter, Randomized, Double-Blind, Phase 3 Trial of Ozanimod Versus Intramuscular Interferon β-1a in Relapsing Multiple Sclerosis (RMS) (P3.410) (2018) (3)
- The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod (2019) (3)
- The role of T cell reactivity to A-beta amyloid peptide in the pathogenic processes associated with Alzheimer's disease (2000) (3)
- Acute evidence of CNS inflammation in patients with mitochondrial diseases. (P4.053) (2015) (2)
- Author Correction: Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature (2020) (2)
- Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS (2022) (2)
- Long-term Efficacy of Delayed-Release Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis According to Prior Therapy: Integrated Analysis of the DEFINE, CONFIRM, and ENDORSE Studies (P7.229) (2015) (2)
- Autoantibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein in paediatric CNS demyelination: Recent developments and future directions. (2012) (2)
- Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study) (2021) (2)
- PO129 Neda analysis by epoch in the opera studies of ocrelizumab (2017) (2)
- Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P01.130) (2012) (2)
- PND63 Effects of BG-12 on Quality of Life in Relapsing–Remitting Multiple Sclerosis: Findings From the Phase 3 Define Study (2012) (2)
- Premature immune senescence in children with MS (2013) (2)
- P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies (2017) (2)
- SclerosisMyelin Surface Antigen in Pediatric Multiple Age-Dependent B Cell Autoimmunity to a (2009) (2)
- GLANCE: A double-blind, randomised, placebo-controlled, parallel-group safety study of natalizumab (Antegren) in combination with glatiramer acetate (Copaxone) in subjects with relapsing-remitting multiple sclerosis (2004) (2)
- Humor in systemic lupus erythematosus. (2014) (2)
- Examining cognitive speed and accuracy dysfunction in youth and young adults with pediatric-onset multiple sclerosis using a computerized neurocognitive battery. (2021) (2)
- 148Immunoablative therapy with purified autologous stem cells rescue for the treatment of poor prognosis MS (2003) (2)
- Immune Response to Seasonal Influenza Vaccination in Patients with Relapsing Multiple Sclerosis Treated with Teriflunomide: The TERIVA Study (P01.169) (2013) (2)
- Neuroradiological efficacy of oral BG-12 for relapsing–/INS;remitting multiple sclerosis (RRMS): Integrated analysis of the Phase 3 DEFINE and CONFIRM studies (2013) (2)
- Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years (4128) (2020) (2)
- 4-Year Follow-up of Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Clinical Efficacy Data From DEFINE, CONFIRM, and the ENDORSE Extension Study (P3.173) (2014) (2)
- OR.61. Abnormal B-Cell Cytokine Response in MS Points to Distinct Roles for Naive and Memory Human B-Cells in Immune Regulation (2006) (2)
- The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents (2022) (2)
- Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials (2018) (2)
- Cross-talk between human glial cells and B cells help propagation of CNS-compartmentalized in progressive MS (2017) (2)
- Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity (2023) (2)
- Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide (2022) (1)
- Rapid Onset of Ocrelizumab Suppression of Brain MRI Activity in Relapsing-Remitting Multiple Sclerosis (S12.008) (2017) (1)
- Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis (2023) (1)
- B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials (2356) (2020) (1)
- B-cell subsets: cellular interactions and relevance in multiple sclerosis (2007) (1)
- Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis. (2022) (1)
- Serologic Response and Clinical Outcomes of SARS-CoV-2 Infection and Vaccination in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis (P2-3.018) (2023) (1)
- Prospective characterization of children positive for anti-MOG antibodies meeting Multiple Sclerosis diagnostic criteria (2019) (1)
- Beta Interferons in Clinically Isolated Syndromes (2008) (1)
- Neural and Immune-Related Molecules in Cerebrospinal Fluid (CSF) of Pediatric-Onset Acquired Demyelinating Syndromes (ADS) of the CNS: Differential Expression in Children Subsequently Diagnosed with Multiple Sclerosis vs. Monophasic Disease (P02.129) (2012) (1)
- Erratum: microRNA dysregulation in multiple sclerosis (2013) (1)
- Phase 1 Clinical Trial of Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis (IN8-2.003) (2012) (1)
- Delayed-release Dimethyl Fumarate-associated Lymphopenia: On-treatment and Post-treatment Implications (2018) (1)
- B cells set trends: Lessons from multiple sclerosis (2012) (1)
- Accumulation of meningeal lymphocytes, but not myeloid cells, correlates with subpial cortical demyelination and white matter lesion activity in progressive MS patients (2021) (1)
- Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005) (2018) (1)
- Baseline Characteristics of Pediatric Patients with Multiple Sclerosis Enrolled in the PARADIGMS Study: A Randomized, Double-Blind Study of Fingolimod versus Interferon-β-1a (P1.347) (2017) (1)
- The CNS barriers differentially regulate the migration of B cells (2014) (1)
- 8th International Congress of Neuroimmunology (2007) (1)
- Sleep-Disordered Breathing (SDB) and Fatigue in Multiple Sclerosis (MS). (2009) (1)
- CCR6 Expression on B Cells Is Not Required for Clinical or Pathological Presentation of MOG Protein–Induced Experimental Autoimmune Encephalomyelitis despite an Altered Germinal Center Response (2021) (1)
- Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the Bold and Expand Trials and their Extensions (2018) (1)
- Neuroinflammation: Ways in Which the Immune System Affects the Brain (2015) (1)
- Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P07.102) (2012) (1)
- Long-term Disability Outcomes in Patients Treated With Teriflunomide for up to 14 Years: Group- and Patient-Level Data From the Phase 2 Extension Study (P6.389) (2018) (1)
- Results from the 48-Week Blinded Extension of RADIANCE: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis (P3.023) (2016) (1)
- Comparative effects of dimethyl and monomethyl fumarate (DMF/MMF) on human myeloid cells. (P4.008) (2015) (1)
- Sequencing the immunopathologic heterogeneity in multiple sclerosis (2015) (1)
- Specific Serum Antibody Patterns Detected with Antigen Arrays Are Associated to the Development of MS in Pediatric Patients (S60.006) (2012) (1)
- Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (2013) (1)
- Multiple sclerosis (PP-038) (2010) (1)
- Ublituximab: a new anti-CD20 agent for multiple sclerosis (2022) (1)
- Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials. (2022) (1)
- Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study (2021) (1)
- Impact Of Obstructive Sleep Apnea-Hypopnea Treatment On Fatigue In Multiple Sclerosis (2010) (1)
- The Effect of IL-10 on M2-Activated Human Microglia (S12.006) (2015) (1)
- Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide (P3.2-096) (2019) (0)
- FTY720 Therapy Results in Selective Redistribution of Circulating Subsets of Effector Memory CD8+ T Cells and NK Cells (2010) (0)
- Late Breaking News (2015) (0)
- F.15. Toll-like Receptor Modulation of Disease Relevant B Cell Responses in MS (2008) (0)
- OR.63. B Cell Depletion in Multiple Sclerosis Results in Diminished Th1 and ThIL-17 Responses by CD4 and CD8 T Cells (2008) (0)
- Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation (2013) (0)
- Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial (2022) (0)
- Safety of the Concurrent Administration of Serotonergic Antidepressants and Ozanimod in Patients With Relapsing Multiple Sclerosis (P7-3.013) (2023) (0)
- Obituary: Ajit Dhaunchak, Ph.D (2013) (0)
- Onset of clinical andMRI e ffi cacy of ocrelizumab in relapsing multiple sclerosis (0)
- Across Brain Endothelial Cells Determinants of Human B Cell Migration (0)
- Delayed−Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes Reported During the Clinical Development Program (S24.006) (2014) (0)
- OR.35. NK Cells Modulate Th17 Responses Following Bone Marrow Transplant Therapy (2009) (0)
- The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics (P6.344) (2017) (0)
- microRNAs Regulate Effector Cytokine Secretion by Human B Cells - Implication for B Cell Cytokine Dysregulation in Multiple Sclerosis (S40.004) (2012) (0)
- Delayed-release Dimethyl Fumarate demonstrates sustained efficacy over nine years in newly diagnosed patients with relapsing-remitting multiple Sclerosis (2019) (0)
- T-cell antigens in pediatric-onset multiple sclerosis: A unique window into early disease mechanisms (2017) (0)
- Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study (2022) (0)
- Profiling of Peripheral Blood Lymphocytes in Multiple Sclerosis Patients Discontinuing FTY720 Therapy (P05.195) (2013) (0)
- Anti-MOG IgG1 Antibodies in Children (2019) (0)
- OCRELIZUMAB IN PRIMARY PROGRESSIVE MS: THE ORATORIO STUDY (2016) (0)
- Phenotype with Reduced Suppressive Function Effector Regulatory T Cells into a Th17-Like TLR2 Stimulation Drives Human Naive and (2011) (0)
- Preferential Entrapment of Naive T Cells Associates with a Less Diverse T Cell Receptor Repertoire in MS Patients Treated with Fingolimod (P5.296) (2016) (0)
- 57. Depression as a Disease of White Matter Network Disruption: Characterizing the Relationship Between White Matter Lesions and Depression in Patients With Multiple Sclerosis (2023) (0)
- Results of the 48-Week Blinded Extension of RADIANCE: a Randomized, Placebo-controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis (2016) (0)
- TMIC-04. GLIOBLASTOMA-ASSOCIATED MYELOID CELLS DISPLAY NONPOLARIZED M0 MACROPHAGE PHENOTYPE (2016) (0)
- NEUROMYELITIS OPTICA IN THE PEDIATRIC POPULATION (2006) (0)
- Efficacy and Safety of Ozanimod: Results From the 2-Year Blinded Extension of RADIANCE, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Relapsing Multiple Sclerosis (S24.008) (2017) (0)
- Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic (2022) (0)
- Progressive retinal changes in pediatric multiple sclerosis. (2022) (0)
- Immune events following immunoablative therapy for the treatment of multiple sclerosis (MS) (2004) (0)
- MerTK as a Functional Regulator of Anti-Inflammatory Myelin Phagocytosis by Human Myeloid Cells (P5.273) (2016) (0)
- 147 Siponimod preserves retinal thickness: findings from the EXPAND OCT substudy (2022) (0)
- CS02-6. Aberrant transcriptional program regulating naive CD4 T-cell activation defines a progressive Multiple Sclerosis subgroup (2011) (0)
- Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis (2022) (0)
- Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases (2022) (0)
- Psychiatric Aspects of Neurology (1997) (0)
- Adverse early life events are not associated with pediatric multiple sclerosis (MS) (P3.217) (2017) (0)
- Human Astrocytes Promote Survival, Activation, and Pro-inflammatory Responses of B Cells: Implications for Multiple Sclerosis (2010) (0)
- Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis (S33.007) (2017) (0)
- Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study (2021) (0)
- LOOKING AHEAD: THE FUTURE OF MULTIPLE SCLEROSIS* (2006) (0)
- Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis (P5-3.010) (2023) (0)
- Author response to Dr. Kearney (2019) (0)
- Evidence of in vivo Immune Modulation with Vitamin D3 and Calcium Supplementation in Multiple Sclerosis (2010) (0)
- Prospective clinical and MRI characterization of children with serum anti-MOG antibodies meeting the multiple sclerosis diagnostic criteria (2018) (0)
- Human Mesenchymal Stem Cell (MSC) Products Suppress Th1 but Induce Th17 Responses (2010) (0)
- In situ microRNA profiles of astrocytes in the context of ischemic brain injury and multiple sclerosis (2014) (0)
- RPC1063 Safe and Effective in RRMS (2014) (0)
- Pediatric-Onset Multiple Sclerosis as a Window Into Early Disease Targets and Mechanisms (2016) (0)
- F.14. Autoantibodies to Myelin Oligodendrocyte Glycoprotein in Pediatric MS (2008) (0)
- Samuel Ludwin: Obituary (2020) (0)
- CTLA4 engagement can have both positive and negative effects on human T cell activation (1998) (0)
- B cell-based therapies for multiple sclerosis and related diseases (2007) (0)
- 115 Impact of siponimod on myelination across SPMS subgroups: post-hoc analysis from EXPAND MRI substudy (2022) (0)
- expressing the type-II transmembrane serine protease matriptase Initiation of plasminogen activation on the surface of monocytes (2011) (0)
- ACTRIMS-ECTRIMS MSBoston 2014: Late Breaking News Oral Presentations (2014) (0)
- Changes in the Immune Cell Profile, Clinical and Safety Outcomes in Fingolimod-Treated Patients with Relapsing Multiple Sclerosis: Interim Results of the FLUENT Study (2019) (0)
- Considering a career in neurology research? Heed these words (2013) (0)
- Relationship Between Infections and Absolute Lymphocyte Count During Phase 3 and Open-label Extension Trials of Ozanimod in Patients With Relapsing Multiple Sclerosis (P7-3.002) (2023) (0)
- Human B cell and glial cell interactions: Implications to the compartmentalized CNS inflammation of multiple sclerosis (MS) (2014) (0)
- Distinct stage-specific transcriptional states of B cells derived from human tonsillar tissue (2023) (0)
- Multiple sclerosis meets systems immunology – Authors' reply (2021) (0)
- Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis Using a Composite Measure of Disability: Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P2.144) (2016) (0)
- 159 Delayed-release dimethyl fumarate–associated lymphopenia (2019) (0)
- Effects of Polarized Human Lymphocytes and Myeloid Cells on Astrocyte Responses and Oligodendrocyte Differentiation (S14.007) (2014) (0)
- 043 Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis (2022) (0)
- First Night Effect And Diagnosis Of Obstructive Sleep Apnea In Multiple Sclerosis (2012) (0)
- OR.96. The Abrogation of Inflammatory Disease Activity in MS Patients Treated with Immune Ablation and Autologous Haematopoetic Stem-cell Transplantation (AHSCT) is Associated with Significant Decreases in ThIL-17, but not Th1 Responses (2008) (0)
- Increased adiponectin levels in serum of early pediatric onset MS induce pro-inflammatory responses of both myeloid cells and T cells (2014) (0)
- An integrated analysis of the clinical and neuroradiological effect of BG-12 (dimethyl fumarate) in subgroups of patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINE and CONFIRM studies (2013) (0)
- Proteogenomic immune signatures delineate the landscape of pediatric acquired demyelinating syndromes (2022) (0)
- Author Correction: Neuroimmune disorders of the central nervous system in children in the molecular era (2018) (0)
- Data from: Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice (2019) (0)
- Correction: Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis (2019) (0)
- Neuronal microRNA regulation in Experimental Autoimmune Encephalomyelitis (2018) (0)
- Multiple Sclerosis Therapeutics: B-cell-based therapies for multiple sclerosis (2011) (0)
- MOG-IgG1 antibodies in children. (2018) (0)
- Advances in the Treatment of Neuromyelitis Optica Spectrum Disorders (2020) (0)
- Sa.38. The Effect of Immune Cells on Neurite Outgrowth (2006) (0)
- Neurons Regulate Glial Cell Surface Proteome (P07.089) (2012) (0)
- Distinct Immune Cell Subsets Influence Astrocytes To Express Factors Relevant for Myelin Repair (P05.169) (2013) (0)
- ‘Cytokine defined’ B cell subsets in multiple sclerosis (2014) (0)
- Immune Response Following COVID-19 Vaccination (mRNA or Non-mRNA) in Patients with Relapsing Multiple Sclerosis Treated with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib: An Update (P2-3.017) (2023) (0)
- Relation of Myelin Ingestion with Distinct Polarization Properties of Human Adult Microglia Versus Blood-Derived Macrophages (P02.102) (2012) (0)
- Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis (2018) (0)
- Human Mesenchymal Stem Cells (MSC) Reciprocally Modulate Th1 and Th17 Responses: Role for PGE2 (IN8-2.005) (2012) (0)
- Distinct stage-specific transcriptional states of B cells in human tonsillar tissue (2021) (0)
- Abnormal responses of CD8+CD161high mucosal associated invariant T (MAIT) cells and CCR2+CCR5+ CD4 T cells contribute to disrupted balance of effector and regulatory T cells in pediatric-onset MS (2014) (0)
- Early Clinical and MRI Predictors of Time to Second Attack and Disability in Children with Acute Demyelinating Syndromes: Findings from a Prospective National Cohort Study (S54.007) (2014) (0)
- IgM (and not IgG) oligoclonal bands: Biomarker of targetable inflammation in PPMS (2014) (0)
- Effect of Delayed-Release Dimethyl Fumarate on Total Disability Burden in the CONFIRM Study of Relapsing-Remitting Multiple Sclerosis: Area Under the Curve Analysis of Changes from Baseline in Expanded Disability Status Scale Scores (P7.233) (2015) (0)
- Impact of Pre-analytical Variables Relevant to Multi-centre Studies on the Stability of Serum and Cellular Samples (2010) (0)
- Family health conditions and parental occupational status modify the relationship between pediatric-onset multiple sclerosis and parental health-related quality of life (2023) (0)
- PO127 Composite confirmed disability progression in oratorio (2017) (0)
- B Cells from Blood of Patients with Relapsing-Remitting Multiple Sclerosis Induce Apoptosis in Neurons In Vitro (P1.177) (2014) (0)
- Nervous System Diseases Central Patients with Different Inflammatory Oligodendrocyte Glycoprotein Recognized by Conformational Epitopes on Myelin Distinction and Temporal Stability of (2013) (0)
- OCRELIZUMAB VS INTERFERON β-1A IN RELAPSING MS: TWO STUDIES (2016) (0)
- Bruton tyrosine kinase inhibitors for multiple sclerosis (2023) (0)
- Development Of Silent Brain Lesions In Pediatric Patients With Antibodies To Myelin Oligodendrocyte Glycoprotein (2020) (0)
- Effects of Ocrelizumab on Neurofilament Light Chain and Other Biomarkers of Neuroinflammation and Neurodegeneration in MS: OBOE Study Design (P6.337) (2017) (0)
- The Relation between Meningeal Inflammation, Cortical Demyelination and White Matter Lesional Activity in Chronic Multiple Sclerosis: a Pilot Study (P5.228) (2015) (0)
- Reply (2010) (0)
- Serum 25‐hydroxyvitamin D as a determinant of multiple sclerosis outcome following a pediatric demyelinating event (2009) (0)
- Peripheral immune cell profiles in fingolimod treated multiple sclerosis patients following short term drug interruption (P1.155) (2015) (0)
- Establishment of an Efficient Validation Strategy for Reliable High-throughput Protein Quantification with Multiplex Bead-based Luminex Immunoassays (2010) (0)
- Retinal Nerve Fiber Layer (RNFL) and Ganglion Cell Inner Plexiform Layer (GCIPL) in Persistently Myelin Oligodendrocyte Glycoprotein Antibody Positive Youth (P3.330) (2018) (0)
- TLR2 stimulation drives human CD4+CD25+CD127negFOXP3+ Tregs into a Th17-like phenotype with reduced suppressive function. (50.4) (2011) (0)
- Inter-scanner brain MRI volumetric biases persist even in a harmonized multi-subject study of multiple sclerosis (2022) (0)
- Effects of Fingolimod on MRI Outcomes in Patients with Pediatric Onset Multiple Sclerosis: Results from Phase 3 PARADIGMS Study (S51.005) (2018) (0)
- A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS (2016) (0)
- FTY 720-Treated Multiple Sclerosis Patients NK Lymphocyte Subset inbright Reduction of the Peripheral Blood CD 56 (2011) (0)
- 118 Sustained reduction of disability and cognitive decline with long-term siponimod in EXPAND active SPMS patients (2022) (0)
- 2010 McDonald Criteria for Diagnosing Pediatric Multiple Sclerosis (P01.155) (2012) (0)
- Effect of CD28/CTLA4 signaling on function of MBP reactive T cells (1998) (0)
- PO128 Infusion-related reactions with ocrelizumab in rms and ppms (2017) (0)
- Final Outcomes of the Teriflunomide Phase 2 Extension Study: 13 Years of Efficacy and Safety Results (P3.027) (2016) (0)
- Human B Cell Cytokine Regulation and Multiple Sclerosis (MS) (2007) (0)
- Phenotypic and Functional Analysis of Immune Cell Subsets in Pediatric-onset Multiple Sclerosis (MS): Towards Definition of Earliest Disease Mechanisms (P2.236) (2014) (0)
- Editorial: Update on Translational Neuroimmunology - Research of ISNI 2018 (2020) (0)
- Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial (2022) (0)
- CTLA4 blockade enhances B7-2 dependent Th-2 cytokine production from human MBP-reactive T-cells (1998) (0)
- Sleep-disordered Breathing Is Associated With Pain In Multiple Sclerosis (2010) (0)
- NEUROIMMUNOLOGY OF MS : CURRENT CONCEPTS * — (0)
- Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS (2020) (0)
- Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis (2020) (0)
- Fingolimod Treatment in Multiple Sclerosis Increases the Ability of Circulating T Cells To Regulate Pro-Inflammatory Th1 and Th17 T Cell Responses (S31.003) (2012) (0)
- A.02 Serum biomarkers of MS disease activity in patients treated with bone marrow transplant (2019) (0)
- Reassessing B cell contributions in multiple sclerosis (2018) (0)
- A Further TWEAK to Multiple Sclerosis Pathophysiology (2013) (0)
- MRI Features Distinguish Monophasic ADEM from MS: Findings from a Canadian Cohort of Children with Incident CNS Demyelination (S50.002) (2012) (0)
- A new activation assay reveals abnormal myelin and EBV antigen-reactivities superimposed on abnormal ‘autoactivation’ in pediatric multiple sclerosis (2800) (2020) (0)
- Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood (2022) (0)
- Prospective Monitoring of in Vivo Biological Effects of Natalizumab (Avla-4, Tysabri®) in Patients with Ms (2006) (0)
- Biomarkers in Pediatric Multiple Sclerosis: Predicting Recurrent Disease at the Initial Demyelinating Episode (2010) (0)
- 3285 Toxicity of Released B Cell Products in Multiple Sclerosis: Effects on Neurons and Oligodendrocytes (2019) (0)
This paper list is powered by the following services:
